Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT03999099
PHASE1

Targeting Orexin to Treat Nicotine Dependence

Sponsor: Mclean Hospital

View on ClinicalTrials.gov

Summary

Tobacco smoking continues to be the primary cause of preventable mortality in the United States. Despite the availability of smoking cessation aids, the majority of those trying to quit smoking end up relapsing. Thus, there is a strong need to evaluate alternative treatment targets such as orexin antagonists, which have shown promise in preclinical models at reducing the motivational aspects of drug use.The current work will evaluate the influence of orexin antagonism on several factors impacting the motivation to smoke.

Key Details

Gender

All

Age Range

18 Years - 50 Years

Study Type

INTERVENTIONAL

Enrollment

4

Start Date

2019-09-26

Completion Date

2023-07-31

Last Updated

2026-09-21

Healthy Volunteers

No

Interventions

DRUG

Suvorexant 20 mg

Suvorexant at a high dose (20 mg)

DRUG

Suvorexant 10 mg

Suvorexant at a low dose (10 mg)

DRUG

Placebo oral tablet

Placebo

Locations (1)

McLean Hospital

Belmont, Massachusetts, United States